Mara Goldstein
Stock Analyst at Mizuho
(1.94)
# 997
Out of 4,479 analysts
62
Total ratings
33.33%
Success rate
-6.03%
Average return
Main Sectors:
Top Industries:
24 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $14.65 | +186.69% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $18.26 | +173.82% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $20.66 | +117.81% | 1 | Dec 22, 2023 | |
| KURA Kura Oncology | Initiates: Buy | $26 | $20.58 | +26.34% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $59.02 | +30.46% | 4 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $2.32 | +201.72% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $3.22 | +148.45% | 3 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $1.69 | +610.06% | 5 | Nov 20, 2023 | |
| IOVA Iovance Biotherapeutics | Reiterates: Buy | $30 | $7.73 | +288.10% | 4 | Sep 15, 2023 | |
| VSTM Verastem | Reiterates: Buy | $36 | $2.94 | +1,126.58% | 5 | Aug 29, 2023 | |
| NKTR Nektar Therapeutics | Reiterates: Neutral | $6 | $1.17 | +412.82% | 3 | Aug 7, 2023 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Neutral | $3.5 | $1.78 | +96.63% | 4 | Jun 16, 2023 | |
| INAB IN8bio | Reiterates: Buy | $12 | $0.81 | +1,384.60% | 2 | Apr 24, 2023 | |
| IMRX Immuneering | Upgrades: Buy | $10 → $20 | $1.09 | +1,734.86% | 2 | Apr 19, 2023 | |
| MRK Merck & Co. | Reiterates: Buy | $130 | $127.72 | +1.79% | 2 | Apr 10, 2023 | |
| CTMX CytomX Therapeutics | Maintains: Neutral | $4 → $2 | $1.32 | +51.52% | 3 | Mar 28, 2023 | |
| AUTL Autolus Therapeutics | Maintains: Buy | $18 → $12 | $3.38 | +255.03% | 2 | Mar 8, 2023 | |
| ADAP Adaptimmune Therapeutics | Upgrades: Buy | $9 | $1.05 | +757.14% | 2 | Nov 9, 2022 | |
| EFTR eFFECTOR Therapeutics | Initiates: Buy | $500 | $0.18 | +277,677.78% | 1 | Oct 4, 2021 | |
| ARRY Array Technologies | Initiates: Overweight | n/a | $9.63 | - | 3 | Jan 15, 2019 | |
| CYTK Cytokinetics | Initiates: Overweight | n/a | $54.84 | - | 2 | Sep 21, 2018 | |
| CLDX Celldex Therapeutics | Downgrades: Neutral | n/a | $37.01 | - | 2 | Apr 17, 2018 | |
| ADXS Ayala Pharmaceuticals | Maintains: Overweight | n/a | $0.28 | - | 1 | Mar 13, 2018 | |
| ARDX Ardelyx | Maintains: Overweight | n/a | $5.28 | - | 1 | Oct 12, 2017 |
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $14.65
Upside: +186.69%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $18.26
Upside: +173.82%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $20.66
Upside: +117.81%
Kura Oncology
Dec 22, 2023
Initiates: Buy
Price Target: $26
Current: $20.58
Upside: +26.34%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $59.02
Upside: +30.46%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $2.32
Upside: +201.72%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $3.22
Upside: +148.45%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $1.69
Upside: +610.06%
Iovance Biotherapeutics
Sep 15, 2023
Reiterates: Buy
Price Target: $30
Current: $7.73
Upside: +288.10%
Verastem
Aug 29, 2023
Reiterates: Buy
Price Target: $36
Current: $2.94
Upside: +1,126.58%
Nektar Therapeutics
Aug 7, 2023
Reiterates: Neutral
Price Target: $6
Current: $1.17
Upside: +412.82%
Corvus Pharmaceuticals
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $1.78
Upside: +96.63%
IN8bio
Apr 24, 2023
Reiterates: Buy
Price Target: $12
Current: $0.81
Upside: +1,384.60%
Immuneering
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $1.09
Upside: +1,734.86%
Merck & Co.
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $127.72
Upside: +1.79%
CytomX Therapeutics
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $1.32
Upside: +51.52%
Autolus Therapeutics
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $3.38
Upside: +255.03%
Adaptimmune Therapeutics
Nov 9, 2022
Upgrades: Buy
Price Target: $9
Current: $1.05
Upside: +757.14%
eFFECTOR Therapeutics
Oct 4, 2021
Initiates: Buy
Price Target: $500
Current: $0.18
Upside: +277,677.78%
Array Technologies
Jan 15, 2019
Initiates: Overweight
Price Target: n/a
Current: $9.63
Upside: -
Cytokinetics
Sep 21, 2018
Initiates: Overweight
Price Target: n/a
Current: $54.84
Upside: -
Celldex Therapeutics
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $37.01
Upside: -
Ayala Pharmaceuticals
Mar 13, 2018
Maintains: Overweight
Price Target: n/a
Current: $0.28
Upside: -
Ardelyx
Oct 12, 2017
Maintains: Overweight
Price Target: n/a
Current: $5.28
Upside: -